Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Dec 07, 2022 7:21pm
230 Views
Post# 35157786

RE:KSW thanks for that comprehensive analysis but

RE:KSW thanks for that comprehensive analysis butYes, Im curious to see a N.R. out of the presentaions today.
The tweet postd on a big enough screen does reveal positive reaction/
"pela pimes the immune system"
Not sure why no N.R. ?
Ahe A.N. abstract seems to be a wild card.
Regarding the SP & potential buyout.

The value of ONC as a buyout has absoutly zero to do with trading share price.
It has the do with the "present value of potential forward income"
Meaning what can ONC/Pela bring to the table for an aquiring company.
Many many private companies are bought out with essentially zero share trading value
ONC(Y) just so happens to be public traded & manipulated by day trades & shortsellers.
Check out this link on "explaining Biotech valuation"
Notice..not once does it mention trading shareprice value.
An aquiring pharma would be buying the potential opportunity/income from Pela sales.

https://www.investopedia.com/articles/stocks/06/biotechvaluation.asp#:~:text=Portfolio%20Valuation%20Approach,-Think%20of%20a&text=In%20other%20words%2C%20you%20determine,whole%20company%20is%20worth%20today.
<< Previous
Bullboard Posts
Next >>